Zamagni E - Search Results

1

Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.

Gozzetti A, Guarnieri A, Zamagni E, Zakharova E, Coriu D, Bittrich M, Pika T, Tovar N, Schutz N, Ciofini S, Peña C, Rocchi S, Rassner M, Avivi I, Waszczuk-Gajda A, Chhabra S, Usnarska-Zubkiewicz L, González-Calle V, Mateos MV, Bocchia M, Bigi F, Füllgraf H, Bhasin-Chhabra B, Gentile M, Davila J, Vesole DH, Cavo M, Thapa B, Crusoe E, Einsele H, Legiec W, Charliński G, Jurczyszyn A. Gozzetti A, et al. Among authors: zamagni e. Am J Hematol. 2022 Jul;97(7):877-884. doi: 10.1002/ajh.26566. Epub 2022 Apr 20. Am J Hematol. 2022. PMID: 35389534 Free PMC article.

2

High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.

Cavo M, Bandini G, Benni M, Gozzetti A, Ronconi S, Rosti G, Zamagni E, Lemoli RM, Bonini A, Belardinelli A, Motta MR, Rizzi S, Tura S. Cavo M, et al. Among authors: zamagni e. Bone Marrow Transplant. 1998 Jul;22(1):27-32. doi: 10.1038/sj.bmt.1701280. Bone Marrow Transplant. 1998. PMID: 9678792

3

Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy.

Lemoli RM, Martinelli G, Zamagni E, Motta MR, Rizzi S, Terragna C, Rondelli R, Ronconi S, Curti A, Bonifazi F, Tura S, Cavo M. Lemoli RM, et al. Among authors: zamagni e. Blood. 2000 Apr 1;95(7):2234-9. Blood. 2000. PMID: 10733490 Free article.

4

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.

Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, Bandini G, Motta MR, Testoni N, Amabile M, Ottaviani E, Vianelli N, de Vivo A, Gozzetti A, Tura S, Cavo M. Martinelli G, et al. Among authors: zamagni e. J Clin Oncol. 2000 Jun;18(11):2273-81. doi: 10.1200/JCO.2000.18.11.2273. J Clin Oncol. 2000. PMID: 10829048

5

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M. Tosi P, et al. Among authors: zamagni e. Leukemia. 2000 Jul;14(7):1310-3. doi: 10.1038/sj.leu.2401819. Leukemia. 2000. PMID: 10914557

6

Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.

Tosi P, Ronconi S, Zamagni E, Cellini C, Grafone T, Cangini D, Pileri SA, Baccarani M, Tura S, Cavo M. Tosi P, et al. Among authors: zamagni e. Haematologica. 2001 Apr;86(4):409-13. Haematologica. 2001. PMID: 11325648 Clinical Trial.

7

Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.

Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S; Writing Committee of the "Bologna 90" Clinical Trial. Cavo M, et al. Among authors: zamagni e. Haematologica. 2002 Sep;87(9):934-42. Haematologica. 2002. PMID: 12217805 Clinical Trial.

8

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G. Soverini S, et al. Among authors: zamagni e. Blood. 2003 Sep 1;102(5):1588-94. doi: 10.1182/blood-2002-12-3789. Epub 2003 May 1. Blood. 2003. PMID: 12730120 Free article. Clinical Trial.

9

First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M. Cavo M, et al. Among authors: zamagni e. Haematologica. 2004 Jul;89(7):826-31. Haematologica. 2004. PMID: 15257934 Clinical Trial.

10

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study. Cavo M, et al. Among authors: zamagni e. Blood. 2005 Jul 1;106(1):35-9. doi: 10.1182/blood-2005-02-0522. Epub 2005 Mar 10. Blood. 2005. PMID: 15761019 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

178 results

Search Page